Stem cells of GATA1-related leukemia undergo pernicious changes after 5-fluorouracil treatment

Experimental Hematology

Volumn 37, Issue 4, 2009, Pages

  Abe, Kanako ^a   Shimizu, Ritsuko ^a   Pan, Xiaoqing ^b   Hamada, Hiromi ^a   Yoshikawa, Hiroyuki ^a   Yamamoto, Masayuki ^a,b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; HOE 33342; TRANSCRIPTION FACTOR GATA 1;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE; CELL FRACTIONATION; CELL POPULATION; CELL STIMULATION; CELL STRUCTURE; CELL TRANSPLANTATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; GENE EXPRESSION; GENETIC LINKAGE; HEMATOPOIETIC STEM CELL; IMMUNOPHENOTYPING; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; MORPHOLOGICAL TRAIT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; WILD TYPE;

MUS; MUS MUSCULUS;

EID: 62149127778     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.12.004     Document Type: Article

References (48)

1. Dick J.E. Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol 8 (1996) 197-206
2. Huntly B.J., and Gilliland D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5 (2005) 311-321
3. Wang J.C., Lapidot T., Cashman J.D., et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 91 (1998) 2406-2414
4. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994) 645-648
5. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (1997) 730-737
6. Krivtsov A.V., Twomey D., Feng Z., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442 (2006) 818-822
7. Deshpande A.J., Cusan M., Rawat V.P., et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell 10 (2006) 363-374
8. Huntly B.J., Shigematsu H., Deguchi K., et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6 (2004) 587-596
9. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., and Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 17 (2003) 3029-3035
10. Crispino J.D. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol 16 (2005) 137-147
11. Shimizu R., Engel J.D., and Yamamoto M. GATA1-related leukaemias. Nat Rev Cancer 8 (2008) 279-287
12. Pan X., Ohneda O., Ohneda K., et al. Graded levels of GATA-1 expression modulate survival, proliferation, and differentiation of erythroid progenitors. J Biol Chem 280 (2005) 22385-22394
13. Shimizu R., Kuroha T., Ohneda O., et al. Leukemogenesis caused by incapacitated GATA-1 function. Mol Cell Biol 24 (2004) 10814-10825
14. Takahashi S., Onodera K., Motohashi H., et al. Arrest in primitive erythroid cell development caused by promoter-specific disruption of the GATA-1 gene. J Biol Chem 272 (1997) 12611-12615
15. Takahashi S., Komeno T., Suwabe N., et al. Role of GATA-1 in proliferation and differentiation of definitive erythroid and megakaryocytic cells in vivo. Blood 92 (1998) 434-442
16. Goodell M.A., Brose K., Paradis G., Conner A.S., and Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183 (1996) 1797-1806
17. Hadnagy A., Gaboury L., Beaulieu R., and Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 312 (2006) 3701-3710
18. Guo Y., Lubbert M., and Engelhardt M. CD34- hematopoietic stem cells: current concepts and controversies. Stem Cells 21 (2003) 15-20
19. Porter E.H., and Berry R.J. The efficient design of transplantable tumour assays. Br J Cancer 17 (1963) 583-595
20. Suzuki N., Ohneda O., Minegishi N., et al. Combinatorial Gata2 and Sca1 expression defines hematopoietic stem cells in the bone marrow niche. Proc Natl Acad Sci U S A 103 (2006) 2202-2207
21. Akashi K., Traver D., Miyamoto T., and Weissman I.L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404 (2000) 193-197
22. Huttmann A., Liu S.L., Boyd A.W., and Li C.L. Functional heterogeneity within rhodamine123(lo) Hoechst33342(lo/sp) primitive hemopoietic stem cells revealed by pyronin Y. Exp Hematol 29 (2001) 1109-1116
23. Arai F., Hirao A., Ohmura M., et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118 (2004) 149-161
24. Gothot A., Pyatt R., McMahel J., Rice S., and Srour E.F. Functional heterogeneity of human CD34(+) cells isolated in subcompartments of the G0 /G1 phase of the cell cycle. Blood 90 (1997) 4384-4393
25. Osawa M., Hanada K., Hamada H., and Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273 (1996) 242-245
26. Huntly B.J.P., and Gilliland D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5 (2005) 311-321
27. So C.W., Karsunky H., Wong P., Weissman I.L., and Cleary M.L. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 103 (2004) 3192-3199
28. Higuchi M., O'Brien D., Kumaravelu P., Lenny N., Yeoh E.J., and Downing J.R. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1 (2002) 63-74
29. Yuan Y., Zhou L., Miyamoto T., et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A 98 (2001) 10398-10403
30. Miyamoto T., Nagafuji K., Akashi K., et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 87 (1996) 4789-4796
31. Ghinasi B., Sanchez M., Martelli F., et al. The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor. Blood 109 (2007) 1460-1471
32. McDevitt M.A., Shivdasani R., Fujiwara Y., Yang H., and Orkin S.H. A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci U S A 94 (1997) 6781-6785
33. Stachura D.L., Chou S.T., and Weiss M.J. Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. Blood 107 (2006) 87-97
34. Vannucchi A.M., Bianchi L., Cellai C., et al. Development of myelofibrosis in mice genetically impaired for GATA-2 expression (GATA-1(low)mice). Blood 100 (2002) 1123-1132
35. low mutation in mice of different genetic back-ground. Blood 106 (2005) 102-113
36. Ito E., Kasai M., Hayashi Y., et al. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome. Br J Haematol 90 (1995) 607-614
37. Gu X., Nagano M., Kanezaki R., et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 102 (2003) 2960-2968
38. Venezia T.A., Merchant A.A., Ramos C.A., et al. Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol 2 (2004) 1640-1651
39. Doyle L.A., and Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22 (2003) 7340-7358
40. Cheng T., Rodrigues N., Shen H., et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287 (2000) 1804-1808
41. Leslie N.R., and Downes C.P. PTEN function: how normal cells control it and tumour cells lose it. Biochem J 382 (2004) 1-11
42. Hambardzumyan D., Becher O.J., Rosenblum M.K., Pandolfi P.P., Manova-Todorova K., and Holland E.C. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22 (2008) 436-448
43. Sussman R.T., Ricci M.S., Hart L.S., Sun S.Y., and El-Deiry W.S. Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther 6 (2007) 1490-1495
44. Dang C.V., O'Donnell K.A., Zeller K.I., Nguyen T., Osthus R.C., and Li F. The c-Myc target gene network. Semin Cancer Biol 16 (2006) 253-264
45. Wilson A., Murphy M.J., Oskarsson T., et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 18 (2004) 2747-2763
46. Takahashi K., and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006) 663-676
47. Wernig M., Meissner A., Cassady J.P., and Jaenisch R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2 (2008) 10-12
48. Nakagawa M., Koyanagi M., Tanabe K., et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26 (2008) 101-106